Recommendations Lowe's price target raised to $195 from $180 at Loop Capital » Lowe's $161.56 / +1.95 (+1.22%) LOW Loop Capital analyst… Story temporarily locked.

To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial Show Hide Related Items >> << Company News

Street Research

Earnings

Periodicals

On The Fly

Options LOW Lowe's $161.56 / +1.95 (+1.22%) 09/22/20 Lowe's to install pickup lockers at all U.S. stores by end of March, 2021 08/28/20 Ackman sees 'corporate inequality' in addition to income inequality 08/21/20 Lowe's raises quarterly cash dividend 9% to 60c per share 08/19/20 Lowe's launches tool rental program nationwide LOW Lowe's $161.56 / +1.95 (+1.22%) 09/18/20 Fly Intel: Top five analyst downgrades 09/18/20 Oppenheimer Oppenheimer downgrades Home Depot, Lowe's on near-term risks 09/18/20 Oppenheimer Lowe's downgraded to Perform from Outperform at Oppenheimer 08/26/20 Jefferies Lowe's price target raised to $205 from $193 at Jefferies LOW Lowe's $161.56 / +1.95 (+1.22%) 08/19/20 Lowe's reports Q2 adj. EPS $3.75, consensus $2.95 08/18/20 Notable companies reporting before tomorrow's open 08/18/20 Notable companies reporting before tomorrow's open 05/20/20 Lowe's withdraws FY20 guidance LOW Lowe's $161.56 / +1.95 (+1.22%) 07/17/20 NFL's brand partnerships to play big safety role for 2020 season, CNBC says LOW Lowe's $161.56 / +1.95 (+1.22%) 09/18/20 Dave & Buster's upgrades among today's top calls on Wall Street 08/19/20 Fly Intel: Wall Street's top stories for Wednesday 08/19/20 Fly Intel: Wall Street's top stories at midday 08/17/20 Fly Intel: Wall Street's top stories at midday LOW Lowe's $161.56 / +1.95 (+1.22%) 08/26/20 Lowe's call volume above normal and directionally bullish 06/17/20 Early notable gainers among liquid option names on June 17th 05/28/20 Lowe's call volume above normal and directionally bullish 05/20/20 Unusually active option classes on open May 20th

Upgrade Deutsche upgrades Tesla with $500 price target on growing tech lead » Tesla $423.90 / -25.41 (-5.66%) TSLA Deutsche Bank analyst… Deutsche Bank analyst Emmanuel Rosner upgraded Tesla to Buy from Hold with a price target of $500, up from $400. Last night's Battery Day showcased an "impressive trajectory" for Tesla's technology, capacity and cost, which should help accelerate the world's shift to electric vehicles and extend the company's lead "considerably," Rosner tells investors in a research note. The stock in premarket trading is down 4.5%, or $19.18, to $405.05. While investor expectations into the event were high, Tesla's plan to achieve 56% reduction in battery cost over the next three years came in "considerably better than anticipated, and could materially boost its volume and margin outlook," says the analyst. Rosner increased Tesla's earnings estimates to incorporate lower battery costs and higher volumes, and the analyst now sees the company delivering 2M-plus vehicles and generating $15 in earnings per share by 2025. With the stock down as traders "sell the news", longer-term investors should take advantage of weakness to buy Tesla as the best way to invest in vehicle electrification, concludes Rosner. Show Hide Related Items >> << Company News

Street Research

Earnings

Syndicate

Periodicals

On The Fly

Options TSLA Tesla $423.90 / -25.41 (-5.66%) 09/22/20 Tesla CEO says very confident can make a $25K electric car in 3 years 09/22/20 Tesla aims for 100GWh by 2022 and 3TWh by 2030 09/22/20 Tesla says new battery yields 5-times energy, 16-times range 09/22/20 Tesla aims to cut cost of battery KWh in half TSLA Tesla $423.90 / -25.41 (-5.66%) 06:44 Today Deutsche Bank Tesla upgraded to Buy from Hold at Deutsche Bank 06:22 Today JMP Securities Tesla's targets would allow it to dominate battery market, says JMP Securities 06:20 Today Piper Sandler Tesla event showed its 'advantage is insurmountable,' says Piper Sandler 06:09 Today Baird Baird names Tesla bearish 'Fresh Pick' on lack of catalysts TSLA Tesla $423.90 / -25.41 (-5.66%) 07/22/20 Tesla reports Q2 adjusted EPS 50c, consensus (11c) 07/22/20 Notable companies reporting after market close 05/10/20 Fly Intel: Top five weekend stock stories 04/29/20 Tesla reports Q1 adjusted EPS $1.24, consensus (36c) TSLA Tesla $423.90 / -25.41 (-5.66%) 09/22/20 Tesla unveils 'tabless' battery cell to reduce EV costs, Verge reports 09/22/20 Tesla CEO sees deliveries rising 30%-40% in 2020, CNBC reports 09/18/20 Court rules in favor of Tesla in case against former employee, Reuters reports 09/17/20 Tesla co-founder gets backing from Amazon for electric battery start-up, FT says TSLA Tesla $423.90 / -25.41 (-5.66%) 09/22/20 Fly Intel: Wall Street's top stories for Tuesday 09/22/20 Fly Intel: Wall Street's top stories at midday 09/22/20 Tesla slips ahead of Battery Day as Musk says 'serious' output not until 2022 09/22/20 Fly Intel: Pre-market Movers TSLA Tesla $423.90 / -25.41 (-5.66%) 09/22/20 Notable open interest changes for September 22nd 09/21/20 Notable open interest changes for September 21st 09/18/20 Notable open interest changes for September 18th 09/18/20 Unusual call flow in option market yesterday

Hot Stocks Eagle Pharmaceuticals: SymBio receives approval of TREAKISYM RTD formulation » Eagle Pharmaceuticals $39.75 / +0.08 (+0.20%) EGRX Eagle Pharmaceuticals… Story temporarily locked.

To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial Show Hide Related Items >> << Company News

Earnings EGRX Eagle Pharmaceuticals $39.75 / +0.08 (+0.20%) 08/19/20 Eagle Pharmaceuticals' dantrolene featured in Journal of Alzheimer's Disease 08/10/20 Eagle lowers R&D Non-GAAP expense view to $40M-$44M 05/04/20 Eagle Pharmaceuticals to request FDA meeting on breast cancer candidate EA-114 04/28/20 Delaware court issues patent decision if favor of Eagle Pharma and Teva EGRX Eagle Pharmaceuticals $39.75 / +0.08 (+0.20%) 08/10/20 Eagle Pharmaceuticals reports Q2 non-GAAP EPS 57c, consensus 23c 05/11/20 Eagle Pharmaceuticals reports Q1 adj. EPS 86c, consensus 57c

Hot Stocks Johnson & Johnson initiates global Phase 3 trial of COVID-19 vaccine candidate » Johnson & Johnson $144.18 / -0.87 (-0.60%) JNJ Johnson & Johnson… Story temporarily locked.

To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial Show Hide Related Items >> << Company News

Street Research

Earnings

Periodicals

On The Fly

Events

Options JNJ Johnson & Johnson $144.18 / -0.87 (-0.60%) 06:49 Today Johnson & Johnson initiates trial for JNJ-78436735 COVID-19 vaccine candidate 09/22/20 Genmab commences arbitration of two matters under license agreement with Janssen 09/22/20 Canada reports agreements with Sanofi and GSK for up to 72M COVID vaccine doses 09/22/20 Pulmatrix provides update on product pipeline JNJ Johnson & Johnson $144.18 / -0.87 (-0.60%) 09/01/20 Morgan Stanley Catalent has potential upside from COVID vaccine, says Morgan Stanley 08/25/20 H.C. Wainwright Momenta downgraded to Neutral from Buy at H.C. Wainwright 08/24/20 Raymond James Momenta initiated with a Market Perform at Raymond James 08/24/20 Raymond James Argenx initiated with an Outperform at Raymond James JNJ Johnson & Johnson $144.18 / -0.87 (-0.60%) 07/16/20 Johnson & Johnson raises FY20 adj. EPS view to $7.75-$7.95 from $7.50-$7.90 07/16/20 Johnson & Johnson reports Q2 adj. EPS $1.67, consensus $1.48 07/15/20 Notable companies reporting before tomorrow's open 07/15/20 Notable companies reporting before tomorrow's open JNJ Johnson & Johnson $144.18 / -0.87 (-0.60%) 09/22/20 FDA to announce tougher standards for coronavirus vaccine, WaPo says 09/04/20 J&J seeks 20K COVID-19 vaccine trial volunteers in Latin America, Reuters says 09/03/20 Pfizer CEO sees coronavirus vaccine data in October, Reuters says 08/28/20 U.K. to fast track COVID-19 vaccine under own regulator, FT says JNJ Johnson & Johnson $144.18 / -0.87 (-0.60%) 09/19/20 Week in review: How Trump's policies moved stocks 09/08/20 Fly Intel: Wall Street's top stories at midday 09/08/20 Moderna slides as analyst says sell on rising COVID vaccine competition 09/03/20 Fly Intel: Wall Street's top stories for Thursday JNJ Johnson & Johnson $144.18 / -0.87 (-0.60%) 08/24/20 Unusually active option classes on open August 24th 07/16/20 Unusually active option classes on open July 16th 06/24/20 Johnson & Johnson call volume above normal and directionally bullish 04/14/20 Unusually active option classes on open April 14th